Ambit Drug Found Effective in Phase I Leukemia Trial
Posted on: Tuesday, 11 December 2007, 12:00 CST
Ambit Biosciences has reported positive results from its ongoing Phase I clinical evaluation of AC220, a small-molecule class III receptor tyrosine kinase inhibitor for the treatment of acute myeloid leukemia.
The Phase I trial is a multi-center, open-label, sequential dose-escalation study that will enroll 20-40 patients with relapsed or refractory acute myeloid leukemia (AML). The preliminary clinical data was based on an AC220 oral solution administered once daily for 14 days followed by a 14 day rest period or immediate continuous dosing. The first two cohorts were reported one at 12 mg/day and the other at 18 mg/day. Dose proportional increases in exposure were seen. Based on 11 patients, no hematological toxicity was observed, and the compound was well absorbed and tolerated. All patients achieved steady plasma levels of the drug within 8-14 days. At the 18 mg dose, trough levels of the drug (free fraction) were several fold greater than the concentration of the compound needed to inhibit the activity of its target, FLT3 kinase, by 50%.
With regard to hematological changes, 3 patients in the 18 mg/day cohort demonstrated improvements. One patient, who remains on AC220, demonstrated a greater than 50% reduction in bone marrow blasts, and one patient demonstrated major platelet-associated hematologic improvement.
In vitro data shows that AC220 has highly selective affinity for several class III RTKs including FLT3, KIT, CSF1R/FMS, RET and PDGFR. With respect to preclinical models of efficacy, in a mouse solid tumor xenograft of a cell line derived from an AML patient, AC220 inhibited tumor growth at 1 mg/kg dosage and caused tumor regression at 3 mg/kg.
Wendell Wierenga, executive vice president of R&D at Ambit, said: "Our kinase screening technology allowed us to optimize AC220 and gave us data on the compound that helped us shape its clinical potential."
Source: Datamonitor
Related Articles
- Data Released Today Demonstrate That Mesalamine Granules Maintain Remission in Ulcerative Colitis Patients Who Switch From Another 5-ASA
- Sunesis Pharmaceuticals Presents Data From Clinical Trials of Voreloxin (Formerly SNS-595) in Patients With Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
- ChemGenex Investigators Present Data on Clinical Activity of Omacetaxine in Imatinib-Resistant Chronic Myeloid Leukemia Patients With the T315I Mutation at ASCO
- ChemGenex Investigators Present Data on Clinical Activity of Omacetaxine in Imatinib-Resistant Chronic Myeloid Leukemia Patients With the T315I Mutation at International Leukemia Conference
- BARACLUDE(R) (Entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-Naive Chronic Hepatitis B Patients
- EarlySense Receives FDA Clearance for Its Contact-Free Patient's Clinical Status Monitor
- Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
- MEDecision's Patient Clinical Summary To Be Implemented By Memphis Managed Care Corporation
- Chiron Announces Promising Data From Clinical Study of Adjuvanted Avian Influenza Vaccine
- ARIAD Reports Positive Early Phase 2 Results on AP23573, Novel mTOR Inhibitor, in Patients With Advanced Sarcomas at ASCO; Data Show Clinical Benefit and Symptomatic Improvement
 |
 |
User Comments (0)
RSS Feeds